Lifetime risk factors for cognitive and functional decline in Alzheimer’s disease (AD) are not fully understood, and were prospectively evaluated in patients with low mean schooling from São Paulo, Brazil. Consecutive outpatients with late-onset AD were assessed for APOE haplotypes and the following potential baseline predictors: gender, schooling, age at dementia onset, lifetime urban living and sanitary conditions, occupational complexity, cognitive and physical activities, cerebrovascular risk factors (obesity, lifetime alcohol use and smoking, length of arterial hypertension, diabetes mellitus, and a dyslipidemic profile), use of a pacemaker, creatinine clearance, body mass index, waist circumference, head traumas with unconsciousness, treated systemic bacterial infections, amount of surgical procedures under general anesthesia, and family history of AD. Participants were followed from October 2010 to May 2017 for baseline risk factor associations with time since dementia onset for Clinical Dementia Rating and Mini-Mental State Examination score changes. For 227 patients (154 women, 119 APOE ε 4 carriers), later AD onset (mean 73.60±6.4 years-old, earlier for APOE ε 4/ε 4 carriers, p < 0.001) was the only variable hastening all endpoints, baseline creatinine clearance and lifetime alcohol use were hazardous for earlier cognitive and functional endpoints, women had earlier cognitive endpoints only, and schooling had a cumulative protective effect over later cognitive endpoints, particularly for carriers of APOE ε 4. Exclusively for carriers of APOE ε 4, head traumas with unconsciousness were hazardous for earlier cognitive endpoints, while lifetime sanitary conditions were protective regarding later cognitive endpoints. Functional and cognitive outcomes in AD represent probable interactions between effects of brain reserve and cerebral perfusion over neurodegeneration.
De OliveiraFF, BertolucciPHF, ChenES, SmithMC
(2014) Risk factors for age at onset of dementia due to Alzheimer’s disease in a sample of patients with low mean schooling from São Paulo, Brazil. Int J Geriatr Psychiatr29, 1033–1039.
2.
OliveiraFF, ChenES, SmithMC, BertolucciPHF
(2016) Predictors of cognitive and functional decline in patients with Alzheimer disease dementia from Brazil. Alzheimer Dis Assoc Disord30, 243–250.
3.
OliveiraFF, ChenES, SmithMC, BertolucciPHF
(2017) Associations of cerebrovascular metabolism genotypes with neuropsychiatric symptoms and age at onset of Alzheimer’s disease dementia. Rev Bras Psiquiatr39, 95–103.
4.
TostoG, BirdTD, BennettDA, BoeveBF, BrickmanAM, CruchagaC, FaberK, ForoudTM, FarlowM, GoateAM, Graff-RadfordNR, LantiguaR, ManlyJ, OttmanR, RosenbergR, SchaidDJ, SchupfN, SternY, SweetRA, MayeuxR
(2016) The role of cardiovascular risk factors and stroke in familial Alzheimer disease. JAMA Neurol73, 1231–1237.
5.
RoherAE, KokjohnTA, BeachTG
(2006) An association with great implications: Vascular pathology and Alzheimer disease. Alzheimer Dis Assoc Disord20, 73–75.
6.
De OliveiraFF, BertolucciPHF, ChenES, SmithMAC
(2014) Pharmacological modulation of cognitive and behoral symptoms in patients with dementia due to Alzheimer’s disease. J Neurol Sci336, 103–108.
7.
EricksonMA, BanksWA
(2013) Blood-brain barrier dysfunction as a cause and consequence of Alzheimer’s disease. J Cereb Blood Flow Metab33, 1500–1513.
8.
RogalskiEJ, RademakerA, HarrisonTM, HelenowskiI, JohnsonN, BigioE, MishraM, WeintraubS, MesulamMM
(2011) ApoE E4 is a susceptibility factor in amnestic but not aphasic dementias. Alzheimer Dis Assoc Disord25, 159–163.
9.
ZhangT, LiuS, ZhangY, GuanY, WangX, ZhaoL, ShiZ, YueW, ZhangY, LiuS, JiY
(2017) Apolipoprotein E e4 allele is associated with subjective cognitive decline: A meta-analysis. Neuroepidemiology49, 165–173.
10.
FerrariC, XuWL, WangHX, WinbladB, SorbiS, QiuC, FratiglioniL
(2013) How can elderly apolipoprotein E ε 4 carriers remain free from dementia?Neurobiol Aging34, 13–21.
11.
BlennowK, de LeonMJ, ZetterbergH
(2006) Alzheimer’s disease. Lancet368, 387–403.
12.
InouyeSK, MarcantonioER, KosarCM, TommetD, SchmittEM, TravisonTG, SaczynskiJS, NgoLH, AlsopDC, JonesRN
(2016) The short-term and long-term relationship between delirium and cognitive trajectory in older surgical patients. Alzheimers Dement12, 766–775.
13.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarilloMC, ThiesB, WeintraubS, PhelpsCH
(2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement7, 263–269.
14.
De OliveiraFF, BertolucciPHF, ChenES, SmithMC
(2014) Assessment of risk factors for earlier onset of sporadic Alzheimer’s disease dementia. Neurol India62, 625–630.
15.
NajAC, JunG, ReitzC, KunkleBW, PerryW, ParkYS, BeechamGW, RajbhandaryRA, Hamilton-NelsonKL, WangLS, KauweJSK, HuentelmanMJ, MyersAJ, BirdTD, BoeveBF, BaldwinCT, JarvikGP, CranePK, RogaevaE, BarmadaMM, DemirciFY, CruchagaC, KramerPL, Ertekin-TanerN, HardyJ, Graff-RadfordNR, GreenRC, LarsonEB, St George-HyslopPH, BuxbaumJD, EvansDA, SchneiderJA, LunettaKL, KambohMI, SaykinAJ, ReimanEM, De JagerPL, BennettDA, MorrisJC, MontineTJ, GoateAM, BlackerD, TsuangDW, HakonarsonH, KukullWA, ForoudTM, MartinER, HainesJL, MayeuxRP, FarrerLA, SchellenbergGD, Pericak-VanceMA
(2014) Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: A genome-wide association study. JAMA Neurol71, 1394–1404.
16.
ChavesMLF, CamozzatoAL, GodinhoC, KochhannR, SchuhA, AlmeidaVL, KayeJ
(2007) Validity of the clinical dementia rating scale for the detection and staging of dementia in Brazilian patients. Alzheimer Dis Assoc Disord21, 210–217.
17.
FolsteinMF, FolsteinS, McHughPR
(1975) Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
18.
ChobanianAV, BakrisGL, BlackHR, CushmanWC, GreenLA, IzzoJLJr, JonesDW, MatersonBJ, OparilS, WrightJTJr, RoccellaEJ
(2003) The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure – the JNC 7 report. JAMA289, 2560–2572.
19.
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
(2003) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care26, S5–S20.
20.
National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
(2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation106, 3143–3421.
21.
CockroftDW, GaultMH
(1976) Prediction of creatinine clearance from serum creatinine. Nephron16, 31–41.
22.
De OliveiraFF, WajmanJR, BertolucciPHF, ChenES, SmithMC
(2015) Correlations among cognitive and behoural assessments in patients with dementia due to Alzheimer’s disease. Clin Neurol Neurosurg135, 27–33.
23.
DeckersK, CamerinoI, van BoxtelMPJ, VerheyFRJ, IrvingK, BrayneC, KivipeltoM, StarrJM, YaffeK, de LeeuwPW, KöhlerS
(2017) Dementia risk in renal dysfunction: A systematic review and meta-analysis of prospective studies. Neurology88, 198–208.
24.
De OliveiraFF, PereiraFV, PiviGAK, SmithMC, BertolucciPHF
(2018) Effects ofhaplotypes and measures of cardiovascular risk over gender-dependent cognitive and functional changes in one year in Alzheimer’s disease. Int J Neurosci128, 472–476.
WinnockM, LetteneurL, Jacqmin-GaddaH, DallongevilleJ, AmouyelP, DartiguesJF
(2002) Longitudinal analysis of the effect of apolipoprotein E e4 and education on cognitive performance in elderly subjects: The PAQUID study. J Neurol Neurosurg Psychiatry72, 794–797.
27.
GorelickPB
(2005) WilliamM. Feinberg Lecture: Cognitive vitality and the role of stroke and cardiovascular disease risk factors. Stroke36, 875–879.
28.
ScarmeasN, ZarahnE, AndersonKE, HabeckCG, HiltonJ, FlynnJ, MarderKS, BellKL, SackeimHA, Van HeertumRL, MoellerJR, SternY
(2003) Association of life activities with cerebral blood flow in Alzheimer disease: Implications for the cognitive reserve hypothesis. Arch Neurol60, 359–365.
29.
DeslandesA, MoraesH, FerreiraC, VeigaH, SilveiraH, MoutaR, PompeuFAMS, CoutinhoESF, LaksJ
(2009) Exercise and mental health: Many reasons to move. Neuropsychobiol59, 191–198.
30.
PortoFHG, CoutinhoAMN, PintoALS, GualanoB, DuranFLS, PrandoS, OnoCR, SpíndolaL, OliveiraMO, ValePHF, NitriniR, BuchpiguelCA, BruckiSMD
(2015) Effects of aerobic training on cognition and brain glucose metabolism in subjects with mild cognitive impairment. J Alzheimers Dis46, 747–760.
31.
DuronE, HanonO
(2008) Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag4, 363–381.
32.
HeymsfieldSB, WaddenTA
(2017) Mechanisms, pathophysiology, and management of obesity. N Engl J Med376, 254–266.
33.
De OliveiraFF, ChenES, SmithMC, BertolucciPHF
(2017) Longitudinal lipid profile variations and clinical change in Alzheimer’s disease dementia. Neurosci Lett646, 36–42.
34.
De OliveiraFF, ChenES, SmithMC, BertolucciPHF
(2016) Associations of blood pressure with functional and cognitive changes in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord41, 314–323.
35.
RuitenbergA, SkoogI, OttA, AevarssonO, WittemanJCM, LernfeltB, van HarskampF, HofmanA, BretelerMMB
(2001) Blood pressure and risk of dementia: Results from the Rotterdam Study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord12, 33–39.
36.
OliveiraFF, MachadoFC, SampaioG, MarinSMC, ChenES, SmithMC, BertolucciPHF
(2015) Contrasts between patients with Lewy body dementia syndromes and-ε 3/ε 3 patients with late-onset Alzheimer disease dementia. Neurologist20, 35–41.
37.
ShinosakiJSM, RossiniJC, JorgeMLPM, MacedoLBC, TannúsPJ
(2017) Type 1 diabetes, cognition and the neurologist: Exploring Go/No-Go and Maze tasks in the search for a practical screening tool. Int J Dev Neurosci60, 86–93.
38.
WeinsteinG, MaillardP, HimaliJJ, BeiserAS, AuR, WolfPA, SeshadriS, DeCarliC
(2015) Glucose indices are associated with cognitive and structural brain measures in young adults. Neurology84, 2329–2337.
CordonnierC, van der FlierWM, SluimerJD, LeysD, BarkhofF, ScheltensP
(2006) Prevalence and severity of microbleeds in a memory clinic setting. Neurology66, 1356–1360.
41.
KumeK, HanyuH, SatoT, HiraoK, ShimizuS, KanetakaH, SakuraiH, IwamotoT
(2011) Vascular risk factors are associated with faster decline of Alzheimer disease: A longitudinal SPECT study. J Neurol258, 1295–1303.
42.
MusiccoM, PalmerK, SalamoneG, LupoF, PerriR, MostiS, SpallettaG, di IulioF, PettenatiC, CravelloL, CaltagironeC
(2009) Predictors of progression of cognitive decline in Alzheimer’s disease: The role of vascular and sociodemographic factors. J Neurol256, 1288–1295.
43.
ChavesML, CamozzatoAL, KöhlerC, KayeJ
(2010) Predictors of the progression of dementia severity in Brazilian patients with Alzheimer’s disease and vascular dementia. Int J Alzheimers Dis2010, 673581.
44.
SchneiderJA
(2009) High blood pressure and microinfarcts: A link between vascular risk factors, dementia, and clinical Alzheimer’s disease. J Am Geriatr Soc57, 2146–2147.
45.
GuoZ, CupplesLA, KurzA, AuerbachSH, VolicerL, ChuiH, GreenRC, SadovnickAD, DuaraR, DeCarliC, JohnsonK, GoRC, GrowdonJH, HainesJL, KukullWA, FarrerLA
(2000) Head injury and the risk of AD in the MIRAGE study. Neurology54, 1316–1323.
46.
MartinsCAR, OulhajA, de JagerCA, WilliamsJH
(2005) alleles predict the rate of cognitive decline in Alzheimer disease – A nonlinear model. Neurology65, 1888–1893.
47.
De OliveiraFF, ChenES, SmithMC, BertolucciPHF
(2018) Pharmacogenetics of angiotensin-converting enzyme inhibitors in patients with Alzheimer’s disease dementia. Curr Alzheimer Res15, 386–398.
